Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy
 and safety of Tenalisib in 61 patients with CLL who have relapsed or are refractory after at
 least one prior therapy.
Tenalisib is a highly specific and orally available dual PI3K δ/γ inhibitor. Pre-clinical
 experiments demonstrated that Tenalisib is highly effective in killing primary CLL cells in
 vitro. A Phase II study is planned to evaluate the efficacy and safety of Tenalisib in
 patients with relapsed/refractory CLL.
Inclusion Criteria:

 1. Patients with diagnosis of B-cell CLL

 2. Disease status defined as refractory to or relapsed after at least one prior therapy.

 3. Presence of measurable lymphadenopathy presence of > 1 nodal lesion

 4. ECOG performance status ≤ 2.

 5. Adequate bone marrow, liver, and renal function

 Exclusion Criteria:

 1. Richter's (large cell) transformation, or PLL transformation.

 2. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5
 half-lives (whichever is shorter).

 3. Prior exposure to drug that inhibits PI3K

 4. Patient with ASCT/Allo-SCT receiving treatment for active GVHD.

 5. Ongoing severe systemic bacterial, fungal or viral infection.

 6. Central nervous system (CNS) involvement of leukemia or lymphoma.

 7. Ongoing immunosuppressive therapy including systemic corticosteroids.

 8. Known history of severe liver injury as judge by investigator.

 9. Any severe and/or uncontrolled medical conditions or other conditions that could
 affect patient participation

 10. Women who are pregnant or lactating.

 11. Known seropositive requiring anti-viral therapy for i. human immunodeficiency virus
 (HIV) infection. ii. hepatitis B virus (HBV) infection iii. hepatitis c virus (HCV)
 infection iv. active CMV infection

 -